Upgrade to SI Premium - Free Trial

Amgen (AMGN): Raising PT On Repatha Rebound In 2018 - Oppeneheimer

October 26, 2017 6:43 AM
Oppenheimer analyst, Leah Rush Cann, reiterated her Outperform on Amgen (NASDAQ: AMGN) and raised her price target to $205 from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles